Anle138b
Cat. No.：YN380019
CAS No. ：882697-00-9
| 产品名称: | Anle138b |
| CAS No.: | 882697-00-9 |
| Chemical Name: | 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole |
| Synonyms: | Anle138b;Anle-138b;3-(1,3-Benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole;5-(1,3-Benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole;Anle 138b;CID 44608289;BCP32558;Anle138b, >=98% (HPLC);NSC805132;s6782;DB13927;3-(1,3-Benzodioxole-5-yl)-5-(3-bromophenyl)-1H- |
| 分子量: | 343.17 |
| 分子式: | C₁₆H₁₁BrN₂O₂ |
| SMILES: | BrC1=CC(C2=CC(C3=CC=C(OCO4)C4=C3)=NN2)=CC=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Anle138b 是一种低聚物聚集抑 (oligomeric aggregation) 调节剂，可阻断朊病毒蛋白 (PrPSc) 和 α-突触核蛋白 (α-syn) 病理性聚集的形成。Anle138b 在体内强烈抑制低聚物积累、神经元变性和疾病进展。Anle138b 毒性低，口服生物利用度高，血脑屏障通透性好。Anle138b 阻断 Aβ 通道并挽救淀粉样变性小鼠模型的疾病表型。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Wagner, J., Ryazanov, S., Leonov, A., et al.Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's diseaseActa Neuropathol.125(6),795-813(2013)
Brendel, M., Deussing, M., Blume, T., et al.Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tauAlzheimers Res. Ther.11(1),67(2019)
Heras-Garvin, A., Weckbecker, D., Ryazanov, S., et al.Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophyMov. Disord.34(2),255-263(2019)
